Dyadic International (DYAI) IAccess Alpha Virtual Best Ideas Fall Investment Conference 2026 summary

Commercialization progress and product launches

• Transitioned from R&D to commercial stage, now selling multiple products across life sciences, food nutrition, and bioindustrial sectors.

• Products like albumin, transferrin, growth factors, alpha-lactalbumin, and chymosin are available or recently launched.

• Six products are listed and selling through IBT, with direct and partner-driven sales models.

• Initial sales are small but growing, with expectations for a meaningful ramp in early 2027.

• Commercial milestones in the next 12-24 months focus on product launches, partnerships, and licensing agreements.

Revenue models and partnerships

• Revenue streams include direct sales, licensing, milestones, profit-sharing, and royalties.

• Strategic partners like Proliant, INZYMES, Fermbox Bio, and BRIG BIO support commercialization and market access.

• Capital-light strategy leverages partner-driven approaches for products requiring more resources.

• Multiple revenue opportunities from single strains, such as lactoferrin used in both food and life sciences.

• Profit-sharing and royalties diversify income and reduce time to revenue.

Market focus and technology platforms

• Targeting life sciences, food nutrition, and bioindustrial markets, with sub-segments identified for competitive advantage.

• C1 platform focuses on complex proteins for life sciences; Dapibus targets high-yield, low-cost production for food and bioindustrial.

• Addressable markets include $10B in life sciences and $150B in bioindustrial, focusing on niche and specialty opportunities.

• Products serve multiple applications, such as DNase I for gene therapy, diagnostics, and equipment cleaning.

• Emphasis on non-animal, recombinant protein solutions for sustainability and quality.